Buying in as a contrarian play is taking on the risks that Nextstellis is a dud, that dermatology and Contract Services are also duds and that generic margins continue to be squeezed and that Nuvaring never gets approved or too late to have a meaningful impact on sales.
That is a lot of risk.
I am making the same assessment as to whether to sell and take a 60% loss from my initial investment back in Nov'16. The opportunity loss alone is huge.
I believe Nexstellis will be a good investment.
I believe that MYX has developed a solid dermatology business.
I believe that Contract Services is a very good business and is a sleeper.
I could not care less about Nuvaring, it's not there now so why bother being 4th to market.
Ah generics. What a crock. I wish they would sell it.
So my dilemma is: Can Nexstellis+Dermatology+Contract Services overcome the demise in generics with Scott Richards at the helm?
For me the jury is out, but the clock is now ticking very loudly.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)